Description
NVmet is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. It does not produce hypoglycemia. NVmet decreases hepatic glucose production, decreases intestinal absorption of glucose and improve insulin sensitivity by increasing peripheral glucose uptake and utilization.
Presentation
NVmet-500: Each film coated tablet contains Metformin Hydrochloride BP 500 mg.
NVmet-850: Each film coated tablet contains Metformin Hydrochloride BP 850 mg.
NVmet-500 SR: Each sustained release tablet contains Metformin Hydrochloride BP 500 mg.
Side effects
Gastrointestinal symptoms such as diarrhea, nausea, vomiting, abdominal bloating, flatulence and anorexia are the most common side effects of Metformin. These symptoms are generally transient and resolve spontaneously during continued treatment. Because gastrointestinal symptoms during therapy initiation appear to be dose-related, they may be decreased by gradual dose selection and by having patients taken Metformin with meals. Rarely lactic acidosis (approximately 0.03 cases/100 patient-year) can occure due to Metformin accumulation during treatment with Metformin.
Contraindication
Metformin is contraindicated in patients with kidney failure, gastrointestinal disturbance, acute myocardial infarction, diabetic ketoacidosis and hypersensitivity to Metformin.
Caution
Metformin is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive Metformin.
Use in Pregnancy and Lactation
Pregnancy: Metformin is a pregnancy category B drug. While safety in pregnant woman has not been established, Metformin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Reviews
There are no reviews yet.